The U.S. ranked 19th out of 156 countries in happiness, the third consecutive drop in the United Nation’s annual World Happiness Report. (The Washington Post)
The FDA granted breakthrough therapy designation to Axsome Therapeutics’ novel depression treatment AXS-05, an oral NMDA receptor antagonist with multimodal activity.
The FDA cleared the Cervella Cranial Electrotherapy Stimulator, which combines brain-crossing “microcurrent” stimulation with noise-cancelling, Bluetooth-enabled headphones, for the treatment of anxiety, depression, and insomnia, said manufacturer Innovative Neurological Devices.
With the recent approval of the first-ever postpartum depression drug, will Zulresso’s reported $34,000 price tag for a 2.5-day infusion limit access? (Bloomberg)
Exposure to more air pollution — specifically nitrogen dioxide, nitrogen oxides, and particulate matter <2.5 μm and <10 μm in diameter -- was associated with a higher likelihood of a psychotic event in teens. (JAMA Psychiatry)
Analysis of VA records indicated that about 40% of women were given zolpidem (Ambien) at doses higher than the 5-mg maximum as stated in a 2013 FDA safety warning, and, in both sexes, 20% of new users stayed on the drug long-term. (Journal of Clinical Psychiatry)
Over 400 genetic associations across 13 regions of the brain were linked to schizophrenia. (Nature Genetics)
Two generic attention deficit-hyperactivity disorder treatments — methylphenidate hydrochloride extended-release tablets at 8 and 27 mg — launched this week, ANI Pharmaceuticals announced.